- Home
- BSLK vs MBRX Comparison
BSLK vs MBRX Comparison
Compare BSLK & MBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSLK
- MBRX
- Stock Information
- Founded
- BSLK 2009
- MBRX 2015
- Country
- BSLK United States
- MBRX United States
- Employees
- BSLK N/A
- MBRX N/A
- Industry
- BSLK
- MBRX Biotechnology: Pharmaceutical Preparations
- Sector
- BSLK
- MBRX Health Care
- Exchange
- BSLK NYSE
- MBRX Nasdaq
- Market Cap
- BSLK 12.3M
- MBRX 12.9M
- IPO Year
- BSLK N/A
- MBRX 2016
- Fundamental
- Price
- BSLK $2.61
- MBRX $0.31
- Analyst Decision
- BSLK
- MBRX Strong Buy
- Analyst Count
- BSLK 0
- MBRX 3
- Target Price
- BSLK N/A
- MBRX $5.33
- AVG Volume (30 Days)
- BSLK 1.6M
- MBRX 5.2M
- Earning Date
- BSLK 08-21-2025
- MBRX 08-13-2025
- Dividend Yield
- BSLK N/A
- MBRX N/A
- EPS Growth
- BSLK N/A
- MBRX N/A
- EPS
- BSLK N/A
- MBRX N/A
- Revenue
- BSLK $1,525,000.00
- MBRX N/A
- Revenue This Year
- BSLK N/A
- MBRX N/A
- Revenue Next Year
- BSLK N/A
- MBRX N/A
- P/E Ratio
- BSLK N/A
- MBRX N/A
- Revenue Growth
- BSLK N/A
- MBRX N/A
- 52 Week Low
- BSLK $1.75
- MBRX $0.25
- 52 Week High
- BSLK $340.40
- MBRX $4.71
- Technical
- Relative Strength Index (RSI)
- BSLK N/A
- MBRX 24.39
- Support Level
- BSLK N/A
- MBRX $0.25
- Resistance Level
- BSLK N/A
- MBRX $0.42
- Average True Range (ATR)
- BSLK 0.00
- MBRX 0.06
- MACD
- BSLK 0.00
- MBRX -0.03
- Stochastic Oscillator
- BSLK 0.00
- MBRX 13.07
About BSLK BOLT PROJECTS HOLDINGS INC
Bolt Projects Holdings Inc develops and produces biomaterials products. Its flagship products from its Vegan Silk Technology Platform, b-silk and xl-silk, are a biodegradable and vegan protein polymer and a replacement for silicone elastomers in beauty and personal care.
About MBRX Moleculin Biotech Inc.
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.